Comprehensive Financial Health Assessment: CROPSPRAY LTD

1. Financial Health Score: D+

Explanation: Cropspray Ltd is a patient that has recently been discharged from the intensive care unit but remains in a highly fragile state. After years of suffering from chronic financial anemia (negative equity), the company has managed to stabilize its condition and return to positive net assets in the last two years. However, its financial immune system is severely compromised by an extreme reliance on short-term creditor financing and a significant internal blockage (an overdrawn director's loan). While no longer technically insolvent, the slightest financial shock could cause a severe relapse.

2. Key Vital Signs

• Net Assets (Financial Blood Pressure): £10,741 (Up from -£39,588 in 2022). The patient has finally regenerated enough red blood cells to operate above the critical insolvency line. However, with total assets of £302,818 dwarfed by total liabilities of £292,077, the company's blood pressure is dangerously high. For every £1 of assets, the company owes £0.96 to creditors.
• Current Liabilities (Cholesterol Levels): £292,077. All of the company's debts are classified as "falling due within one year." This is akin to having exclusively short-term, high-blood-pressure debt with no long-term stability. The lack of long-term structuring suggests creditors could demand payment at any time, creating a constant risk of financial stroke.
• Director's Loan Account (Arterial Blockage): £70,924 owed by the director. This represents nearly a quarter of the company's total assets. It is a major blockage in the company's financial arteries. Money that should be circulating to pay creditors is currently tied up in the director's personal borrowings.
• Profit Retention (Healing Rate): The transition from negative equity of -£91,520 in 2019 to positive equity of £10,741 in 2024 shows a strong and sustained period of healing and profit retention. The company is generating enough revenue to slowly pay down historical debts.

3. Diagnosis

Chronic High Leverage with Recent Stabilization

The financial data reveals a business that has survived a prolonged period of financial distress. From 2018 through 2022, Cropspray Ltd operated with negative shareholders' funds—meaning the business was technically insolvent and surviving on life support from its creditors and delayed payments.

The turnaround over the last two years is commendable; the patient has stopped the bleeding and is showing signs of financial nutrition. The core business (leasing air passenger transport equipment) appears to be generating the necessary cash flow to chip away at the massive creditor pile.

However, the balance sheet is fundamentally fragile. The "current assets" are heavily reliant on the £70,924 owed by the director. If we strip out this director loan, the company's liquid assets drop to roughly £231,894 against £292,077 of imminent creditor demands. This means the company cannot afford to pay all its current debts if they were called in simultaneously, leaving it highly vulnerable to cash flow seizures.

Furthermore, the micro-entity filing status means we only have a limited view of the company's pulse (no Profit & Loss account is published), but the balance sheet tells a clear story of a business that is over-leveraged and reliant on internal borrowing.

4. Recommendations

To improve financial wellness and build resilience against future shocks, the following treatment plan is prescribed:

1. Clear the Arterial Blockage (Director's Loan): The £70,924 owed by the director must be repaid as a matter of urgency. This will immediately boost the company's cash reserves, lower its blood pressure, and provide the liquidity needed to settle trade creditors without relying on further debt.
2. Debt Restructuring (Blood Pressure Medication): Relying entirely on creditors due within one year is unsustainable. The directors should explore restructuring a portion of this debt into long-term liabilities. Spreading the repayment over a longer period will drastically reduce the day-to-day cash flow pressure.
3. Build an Emergency Reserve (Vitamin Boost): As the company continues its recovery, it is vital to retain profits rather than extract them. Building a cash buffer of at least 3-6 months of operating expenses will ensure the patient can withstand future economic illnesses without relapsing into insolvency.
4. Creditor Communication (Regular Check-ups): Given the high level of creditor reliance, maintaining transparent and proactive communication with key suppliers and lenders is essential to prevent them from unexpectedly calling in their debts.